Endexome commercialises cutting edge technologies developed by one of its partners, CK Cell Technologies. This direct translation from lab-based Research & Development activities to the clinic and beyond makes innovative regenerative medicine solutions available to all Australians. Read more

Proprietary
Processes

Endexome is contributing to the growing global regenerative medicine industry with its exosome-based therapies. We promise to make available exosome-based treatment applications, which mimic the power of cell based therapy but without the associated cost or ethical issues. Read more.

Global
Contribution

Endexome has a proprietary process for the extraction and production of safe, stable and highly active exosomes at scale. The final product (Endexome-Exo) is bioactive, immuno-evasive and lyophilised for easy supply. In this form, the exosomes can be delivered as treatment tools via injection, nasal spray, cream, bandages or micro-needling. Read more.